Stock PHIL PHILOGEN S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-04-26 am EDT 		5-day change 1st Jan Change
18.1 EUR 0.00% Intraday chart for Philogen S.p.A. -0.82% -2.16%
Apr. 12 Indices up; Italy, industrial sales down AN
Apr. 03 Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024

Business Summary

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Number of employees: 165

Sales per Business

EUR in Million2022Weight2023Weight Delta
Product Development 2
86.5 %
- - 20 86.5 % -
Good Manufacturing Practices (GMP) Services
11.3 %
4 18.8 % 3 11.3 % -41.22%
Product Development 1
2.2 %
2 9.4 % 1 2.2 % -77.12%

Sales per region

EUR in Million2022Weight2023Weight Delta
European Union
87.8 %
19 79.3 % 20 87.8 % +7.91%
Extra-European Union (Switzerland)
10.0 %
2 7.5 % 2 10.0 % +29.62%
United States
2.2 %
3 13.1 % 1 2.2 % -83.58%

Managers

Managers TitleAgeSince
Dario Neri CEO
 Chief Executive Officer 60 95-12-31
Duccio Neri FOU
 Founder 61 95-12-31
Laura Baldi DFI
 Director of Finance/CFO 52 -
Katia Lorizzo COO
 Chief Operating Officer - -
Alfredo Covelli CTO
 Chief Tech/Sci/R&D Officer - -
Giovanni Neri BRD
 Director/Board Member 55 95-12-31
Emanuele Puca IRC
 Investor Relations Contact - -
Patrizia Sacchi LAW
 General Counsel - -

Members of the board

Members of the board TitleAgeSince
Sergio Gianfranco Dompé BRD
 Director/Board Member 68 -
Leopoldo Giampaolo Zambeletti BRD
 Director/Board Member 55 -
Duccio Neri FOU
 Founder 61 95-12-31
Giovanni Neri BRD
 Director/Board Member 55 95-12-31
Dario Neri CEO
 Chief Executive Officer 60 95-12-31
Roberto Ferraresi BRD
 Director/Board Member 48 19-05-12
Nathalie Francesca Dompé BRD
 Director/Board Member 37 -
Guido Guidi BRD
 Director/Board Member 71 19-05-12
Maria Giovanna Calloni BRD
 Director/Board Member 59 22-04-30
Marta Bavasso BRD
 Director/Board Member 55 20-12-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 11,368,250 0 0 27.79 %
Stock B 1 29,242,861 11,287,374 ( 38.60 %) 321,515 ( 1.099 %)

Shareholders

NameEquities%Valuation
Sergio Gianfranco Dompé
33.71 %
9,857,236 33.71 % 187 M €
Nerbio SRL
27.69 %
8,098,251 27.69 % 154 M €
Fideuram Asset Management SGR SpA
1.910 %
558,424 1.910 % 11 M €
PHILOGEN S.P.A.
1.099 %
321,515 1.099 % 6 M €
CARTHESIO SA
0.7523 %
220,000 0.7523 % 4 M €
AZ Quest Investimentos Ltda.
0.6839 %
200,000 0.6839 % 4 M €
Azimut Capital Management SGR SpA
0.5605 %
163,912 0.5605 % 3 M €
Mediolanum Gestione Fondi SGRpA
0.4556 %
133,224 0.4556 % 3 M €
Ersel Asset Management SGR SpA
0.1929 %
56,410 0.1929 % 1 M €
AcomeA SGR SpA
0.1539 %
45,000 0.1539 % 855 360 €
NameEquities%Valuation
Nerbio SRL
75.34 %
8,565,018 75.34 % 163 M €
Sergio Gianfranco Dompé
24.66 %
2,803,232 24.66 % 53 M €

Holdings

NameEquities%Valuation
PHILOGEN S.P.A.
1.10%
 321,515 1.10% 6,111,357 $

Company contact information

Philogen SpA

Piazza La Lizza, 7

53100, Siena

+39 05 77206941

http://www.philogen.com
address Philogen S.p.A.(PHIL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Ratings for Philogen S.p.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
18.1 EUR
Average target price
23.5 EUR
Spread / Average Target
+29.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHILOGEN S.P.A. Stock Philogen S.p.A.
-2.16% 779M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PHIL Stock
  4. Company Philogen S.p.A.